Cartalax 20 mg

Cartalax is a synthetic tripeptide with the amino acid sequence Ala-Glu-Asp (also designated as AED or T-31) from the class of short peptide bioregulators, developed within the research school of Professor Vladimir Khavinson. In scientific research, Cartalax is studied as a model compound in cell models for cartilage and connective tissue, particularly chondrocytes (cartilage cells) and fibroblasts (connective tissue cells). It is offered as a freeze-dried powder (lyophilized powder) with a controlled purity of at least 99% (HPLC) and is intended exclusively for laboratory and research purposes.

What is Cartalax?

Cartalax belongs to the short peptide bioregulators: a family of very short, defined peptide sequences described in the Russian peptide literature and catalogued according to the tissue type to which they are coupled in model studies. The molecule is composed of three amino acids—alanine, glutamic acid, and aspartic acid—which are linked via two peptide bonds to form a structurally precisely defined tripeptide with a molecular weight of approximately 333 Da.

Due to their small size, short peptide bioregulators are investigated in the scientific literature as model compounds that may interact with regulatory sequences and the expression of tissue-specific genes in cultured cells. In this context, Cartalax is classified among the bioregulators related to cartilage and connective tissue, thereby serving as a standardized tool for modeling gene expression and cellular dynamics in controlled in vitro systems. The compound is a tool for fundamental research and not a therapeutic or consumer product.

Research areas

In a laboratory context, Cartalax is used in the following research areas, among others:

• In vitro model research into gene expression in chondrocytes (cartilage cells) and fibroblasts (connective tissue cells).
• Model studies regarding the extracellular matrix (ECM) and the dynamics of cartilage and connective tissue in cell culture.
• Research into cell proliferation and cellular differentiation in controlled culture systems.
• Comparative study within the family of short peptide bioregulators (tissue-specific signaling models).
• Studies on the solubility and conformational stability of short synthetic peptides.
• Analytical and structural characterization (HPLC and mass spectrometry reference).

Cartalax compared with related compounds

Cartalax is part of a broader group of short peptide bioregulators, each of which has its own amino acid sequence and associated tissue model system. While Cartalax (Ala-Glu-Asp) is linked to cartilage and connective tissue models in the literature, other members of this family are related to other cell types. The tripeptide Pinealon 20mg (Glu-Asp-Arg), for example, is studied as a model compound in neuronal cell models, while the dipeptide Vilon 20mg (Lys-Glu) and Crystagen 20mg are being investigated in yet other tissue-specific systems. Additionally, for research focusing on the extracellular matrix and collagen models, the matrikine peptide is used. Matrixyl 10 mg a related reference point. This mutual comparison makes the bioregulator family suitable for systematic, sequence-directed in vitro research.

Specifications

Shape, handling and storage

Cartalax is supplied as a freeze-dried powder in a 20 mg vial. In a laboratory setup, the lyophilisate is reconstituted prior to analysis; for short peptides, bacteriostatic water is typically used for this purpose. The freeze-dried powder remains most stable when stored refrigerated and in the dark, protected from light and moisture. After reconstitution, the solution is kept refrigerated (2–8 °C) and protected from repeated temperature fluctuations to maintain the conformational integrity of the peptide. Work with clean, calibrated materials to avoid cross-contamination in analyses.

Want to know more? Read our guide: Bacteriostatic water: what is it used for and how do you mix it correctly?

Purity and lab results

Cartalax is offered with a verified purity of at least 99%, determined via HPLC. For an overview of the available analysis certificates and purity data, please refer to our lab results pageThis ensures that the analytical substantiation remains transparent and verifiable for research purposes.

Frequently Asked Questions

What exactly is Cartalax?
Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp (synonyms AED and T-31), belonging to the short peptide bioregulators. In research, it serves as a model compound in cell models for cartilage and connective tissue.

How does Cartalax differ from other short peptide bioregulators?
Each bioregulator has its own amino acid sequence and is coupled to a different tissue-specific cell model in the literature. Cartalax (Ala-Glu-Asp) is primarily studied in cartilage and connective tissue models, while compounds such as Pinealon or Vilon are investigated in other model systems.

How is Cartalax delivered and stored?
As a freeze-dried powder of 20 mg per vial. Store refrigerated, protected from light and moisture; keep the reconstituted solution refrigerated.

Is Cartalax suitable for human or animal use?
No. Cartalax is supplied exclusively for laboratory and research purposes and is not intended for human or animal consumption.

Where can I find the purity data?
These can be found on our lab results page, where the analytical substantiation is shared.

Intended exclusively for laboratory and research purposes. Not for human or animal consumption, or for medical, diagnostic, therapeutic, or cosmetic use. The buyer is 18+ and confirms the research context. Not a medicine.